First for Women on MSN2mon
New Drug CagriSema May Lead to 10% More Weight Loss Than Wegovy or Ozempic
Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent more weight loss than Wegovy.
Reuters6d
Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows
LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...
Monthly Prescribing Reference1mon
REDEFINE 1 Trial: Superior Weight Loss Seen With CagriSema
CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...
Reuters6d
Novo Nordisk says it has not yet posted details about new CagriSema trial
Mexico's President Claudia Sheinbaum said on Sunday that reason should prevail a day after her government and the U.S. announced tariffs against one another, raising her fist in the air as she ...
Nasdaq1mon
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual ...
Yahoo1mon
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a currently approved medicine but still didn't surpass it. Since Ozempic blasted onto the stage in 2017 with ...
MarketWatch1mon
Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say
Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema ...
Business Insider1mon
Novo Nordisk shares drop 27% premarket after releasing Cagrisema data
06:01 EST Novo Nordisk (NVO) shares drop 27% premarket after releasing Cagrisema data Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming ...
Morningstar1mon
Novo Nordisk: Shares Look Fairly Valued After CagriSema Disappointment
Novo Nordisk disclosed top-line data from the phase 3 Redefine 1 study showing 20.4% placebo-adjusted weight loss for obesity drug candidate CagriSema after 68 weeks of treatment, among patients ...